Research programme: gene therapies for CNS disorders - Voyager Therapeutics

Drug Profile

Research programme: gene therapies for CNS disorders - Voyager Therapeutics

Alternative Names: AAV-delivered gene therapies for CNS disorders - Voyager Therapeutics; AAVrh.10-vectored PHF1; Amyotrophic lateral sclerosis gene therapy - Voyager Therapeutics; Friedreich’s ataxia gene therapy - Voyager Therapeutics; Huntington's disease gene therapy - Voyager Therapeutics; VY FXN01; VY HTT01; VY SMN101; VY SOD101; VY-NAV01; VY-TAU01

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Voyager Therapeutics
  • Class Analgesics; Gene therapies; Monoclonal antibodies
  • Mechanism of Action Gene transference; Nav1.7-voltage-gated-sodium-channel-inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Dementia; Friedreich's ataxia; Huntington's disease; Pain; Spinal muscular atrophy

Most Recent Events

  • 25 Jan 2017 Pharmacodynamics data from preclinical studies in Alzheimer’s disease released by Voyager Therapeutics
  • 20 Oct 2016 Preclinical trials in Alzheimer's disease, Dementia and Pain in USA (Voyager Therapeutics' pipeline, October 2016)
  • 15 Sep 2016 Voyager Therapeutics licenses Gene therapy capsids from the California Institute of Technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top